

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	1585117
<b>Application Number:</b>	10593180
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	8823
<b>Title of Invention:</b>	Pharmaceutical composition and method
<b>First Named Inventor/Applicant Name:</b>	Rachel M. Slade
<b>Customer Number:</b>	26698
<b>Filer:</b>	Jonathan A. Baker/Keri Morris
<b>Filer Authorized By:</b>	Jonathan A. Baker
<b>Attorney Docket Number:</b>	5062.03
<b>Receipt Date:</b>	12-MAR-2007
<b>Filing Date:</b>	
<b>Time Stamp:</b>	17:45:21
<b>Application Type:</b>	U.S. National Stage under 35 USC 371

### Payment information:

Submitted with Payment	no
------------------------	----

### File Listing:

Document Number	Document Description	File Name	File Size(Bytes)	Multi Part /.zip	Pages (if appl.)
1	Information Disclosure Statement (IDS) Filed	5062-03-2007-03-12-IDS-CO V-KM.pdf	82616	no	2

**Warnings:**

<b>Information:</b>					
This is not an USPTO supplied IDS fillable form					
2	Information Disclosure Statement (IDS) Filed	5062-03-2007-03-12-IDS-KM.pdf	198579	no	8
<b>Warnings:</b>					
<b>Information:</b>					
This is not an USPTO supplied IDS fillable form					
3	NPL Documents	01A-Akaho_J-Chem-Software_1-13.pdf	696586	no	13
<b>Warnings:</b>					
<b>Information:</b>					
4	NPL Documents	02A-Amin_CMLS_305-12.pdf	535140	no	8
<b>Warnings:</b>					
<b>Information:</b>					
5	NPL Documents	03A-Andreasen_Arch-Neurology_673-80.pdf	754049	no	8
<b>Warnings:</b>					
<b>Information:</b>					
6	NPL Documents	04A-Bayly_Bio-organic-Chem-Ltr_307-12.pdf	409189	no	6
<b>Warnings:</b>					
<b>Information:</b>					
7	NPL Documents	05A-Bickford_Neuro_Aging_18.pdf	991245	no	11
<b>Warnings:</b>					
<b>Information:</b>					
8	NPL Documents	06A-Blackner_Neurological_294-96.pdf	400362	no	3
<b>Warnings:</b>					
<b>Information:</b>					
9	NPL Documents	07A-Braak_Acta-Neuropathology_239-59.pdf	3987624	no	21
<b>Warnings:</b>					
<b>Information:</b>					

10	NPL Documents	08A-Breitner_Neurobio-Aging_523-30.pdf	538168	no	8
<b>Warnings:</b>					
<b>Information:</b>					
11	NPL Documents	09A-Breitner_Neuro_227-31.pdf	243147	no	3
<b>Warnings:</b>					
<b>Information:</b>					
12	NPL Documents	10A-Camisuli_Behav_Br_89.pdf	863991	no	13
<b>Warnings:</b>					
<b>Information:</b>					
13	NPL Documents	11A-Canaparo_Biomed-Chromatogr_219-26.pdf	381592	no	8
<b>Warnings:</b>					
<b>Information:</b>					
14	NPL Documents	12A-Chen_Nature_975-79.pdf	510348	no	5
<b>Warnings:</b>					
<b>Information:</b>					
15	NPL Documents	13A-Citron_PNAS_13170-75.pdf	573330	no	6
<b>Warnings:</b>					
<b>Information:</b>					
16	NPL Documents	14A-Combs_J-Neurosci_558-67.pdf	892137	no	10
<b>Warnings:</b>					
<b>Information:</b>					
17	NPL Documents	15A-Corton_Annu-Rev-Pharmacol_491-18.pdf	1747646	no	15
<b>Warnings:</b>					
<b>Information:</b>					
18	NPL Documents	16A-Cotran_Path-Basis-Disease_table30-2.pdf	192004	no	1
<b>Warnings:</b>					
<b>Information:</b>					

19	NPL Documents	17A-Cronstein_Annu-Rev-Pharm-Tox_449-62.pdf	1062604	no	8
<b>Warnings:</b>					
<b>Information:</b>					
20	NPL Documents	18A-Cryer_Am-J-Med_413-21.pdf	888075	no	9
<b>Warnings:</b>					
<b>Information:</b>					
21	NPL Documents	19A-DeWitt_Mol-Pharm_625-31.pdf	675399	no	7
<b>Warnings:</b>					
<b>Information:</b>					
22	NPL Documents	20A-Dubois_FASEB_1063-73.pdf	805674	no	11
<b>Warnings:</b>					
<b>Information:</b>					
23	NPL Documents	21A-Eriksen-JL-JCI-Mayo-N SAID.pdf	991224	no	10
<b>Warnings:</b>					
<b>Information:</b>					
24	NPL Documents	22A-Folstein_J-Psychiat_189-98.pdf	814102	no	10
<b>Warnings:</b>					
<b>Information:</b>					
25	NPL Documents	23A-Frautschy_Am-J-Pathol_307-17.pdf	1609847	no	11
<b>Warnings:</b>					
<b>Information:</b>					
26	NPL Documents	24A-Galasko_Alzheimer-Dis ease-Assoc-Disorder_S-33-39.pdf	589507	no	7
<b>Warnings:</b>					
<b>Information:</b>					
27	NPL Documents	25A-Galasko_Arch-Neurol_937-45.pdf	628308	no	9
<b>Warnings:</b>					
<b>Information:</b>					

28	NPL Documents	26A-Halliday_Clin-Exp-Pharmacol_1-8.pdf	791909	no	8
<b>Warnings:</b>					
<b>Information:</b>					
29	NPL Documents	27A-Haugabook_Faseb-J_16-18.pdf	137128	no	3
<b>Warnings:</b>					
<b>Information:</b>					
30	NPL Documents	28A-He_Cell_335-45.pdf	853923	no	11
<b>Warnings:</b>					
<b>Information:</b>					
31	NPL Documents	31A-Kalgutkar_PNAS_925-30.pdf	493339	no	6
<b>Warnings:</b>					
<b>Information:</b>					
32	NPL Documents	29A-Higaki_Neuron_651-59.pdf	868767	no	9
<b>Warnings:</b>					
<b>Information:</b>					
33	NPL Documents	30A-Hsiao_Science_99-102.pdf	396503	no	4
<b>Warnings:</b>					
<b>Information:</b>					
34	NPL Documents	32A-Kalgutkar_J-Med-Chem_2860-70.pdf	735149	no	11
<b>Warnings:</b>					
<b>Information:</b>					
35	NPL Documents	33A-Kato_J-Pharm-Pharmacol_1679-85.pdf	505592	no	7
<b>Warnings:</b>					
<b>Information:</b>					
36	NPL Documents	34A-Kawarabayashi-J_Neurosci_372.pdf	606563	no	10
<b>Warnings:</b>					
<b>Information:</b>					

37	NPL Documents	35A-Khachaturinan_Arch-Neuro_1097-105.pdf	1206117	no	9
<b>Warnings:</b>					
<b>Information:</b>					
38	NPL Documents	36A-Kitamura_Biochem-Biophys-Res_582-86.pdf	411382	no	5
<b>Warnings:</b>					
<b>Information:</b>					
39	NPL Documents	37A-Klafki_J-Biol-Chem_28655-59.pdf	571311	no	5
<b>Warnings:</b>					
<b>Information:</b>					
40	NPL Documents	38A-Koo_J-Biol-Chem_17386-89.pdf	417950	no	4
<b>Warnings:</b>					
<b>Information:</b>					
41	NPL Documents	39A-Koo_J-Cell-Sci_991-98.pdf	646771	no	8
<b>Warnings:</b>					
<b>Information:</b>					
42	NPL Documents	40A-Kopan_PNAS_1683-88.pdf	552515	no	6
<b>Warnings:</b>					
<b>Information:</b>					
43	NPL Documents	41A-Koup_Biopharm-Drug-Dispos_1-15.pdf	1574634	no	15
<b>Warnings:</b>					
<b>Information:</b>					
44	NPL Documents	42A-Lee_Annal-NY-Acad-Sci_261-68.pdf	269498	no	7
<b>Warnings:</b>					
<b>Information:</b>					
45	NPL Documents	43A-Lewis_Nat-Gene_402-5.pdf	602455	no	4
<b>Warnings:</b>					
<b>Information:</b>					

46	NPL Documents	44A-Lim_j-Neurosci_5709-14.pdf	597205	no	6
<b>Warnings:</b>					
<b>Information:</b>					
47	NPL Documents	45A-Lu_Nat-Med_397-04.pdf	657371	no	8
<b>Warnings:</b>					
<b>Information:</b>					
48	NPL Documents	46A-McGeer_Lancet_1037.pdf	179827	no	2
<b>Warnings:</b>					
<b>Information:</b>					
49	NPL Documents	47A-McGeer-Neurology_425.pdf	1205342	no	10
<b>Warnings:</b>					
<b>Information:</b>					
50	NPL Documents	48A-Mckhann_Neurology_939-44.pdf	730086	no	5
<b>Warnings:</b>					
<b>Information:</b>					
51	NPL Documents	49A-McLendon_FASEB_2383-86.pdf	294602	no	4
<b>Warnings:</b>					
<b>Information:</b>					
52	NPL Documents	50A-Mirra_Arch-Pathol-Lab-Med_132-44.pdf	3010131	no	13
<b>Warnings:</b>					
<b>Information:</b>					
53	NPL Documents	51A-Mirra_Neurology_479-86.pdf	1148450	no	8
<b>Warnings:</b>					
<b>Information:</b>					
54	NPL Documents	52A-Mohs_Intl-Psychogeriatric-195-203.pdf	673691	no	9
<b>Warnings:</b>					
<b>Information:</b>					

55	NPL Documents	53A-Montine_Neurology_562-65.pdf	328171	no	4
<b>Warnings:</b>					
<b>Information:</b>					
56	NPL Documents	54A-Murphy_Neuro_Learnin g_64.pdf	344362	no	6
<b>Warnings:</b>					
<b>Information:</b>					
57	NPL Documents	55A-Murphy_J-Biol-Chem_2 6277-84.pdf	727978	no	8
<b>Warnings:</b>					
<b>Information:</b>					
58	NPL Documents	56A-Netland_Neurobio_201- 4.pdf	324059	no	4
<b>Warnings:</b>					
<b>Information:</b>					
59	NPL Documents	57A-Peretto_J-Medicinal-Ch em_A-P.pdf	1162136	no	16
<b>Warnings:</b>					
<b>Information:</b>					
60	NPL Documents	58A-Perez_J-Biol-Chem_18 851-56.pdf	562113	no	6
<b>Warnings:</b>					
<b>Information:</b>					
<b>Total Files Size (in bytes):</b>			45649523		



This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

**New Applications Under 35 U.S.C. 111**

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

**National Stage of an International Application under 35 U.S.C. 371**

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

**New International Application Filed with the USPTO as a Receiving Office**

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.